Free Trial
NASDAQ:OFIX

Orthofix Medical Q2 2025 Earnings Report

Orthofix Medical logo
$11.31 +0.59 (+5.50%)
Closing price 04:00 PM Eastern
Extended Trading
$11.45 +0.14 (+1.24%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Orthofix Medical EPS Results

Actual EPS
N/A
Consensus EPS
$0.04
Beat/Miss
N/A
One Year Ago EPS
N/A

Orthofix Medical Revenue Results

Actual Revenue
N/A
Expected Revenue
$196.89 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Orthofix Medical Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Tuesday, August 5, 2025
Conference Call Time
8:30AM ET

Conference Call Resources

Orthofix Medical Earnings Headlines

This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.
See More Orthofix Medical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Orthofix Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Orthofix Medical and other key companies, straight to your email.

About Orthofix Medical

Orthofix Medical (NASDAQ:OFIX) is a global medical device company specializing in spine and orthopedic solutions. The company develops, manufactures and markets devices designed to treat spinal disorders, musculoskeletal trauma, and bone growth. Its core offerings span advanced spinal implant systems, growth stimulation therapies and biologic products aimed at accelerating fusion and healing in patients with degenerative spinal conditions and complex fractures.

In its spine business, Orthofix provides a comprehensive portfolio that includes minimally invasive and open surgical fixation systems, interbody fusion devices and dynamic stabilization technologies. The company’s bone growth stimulation products leverage pulsed electromagnetic field (PEMF) technology to promote bone repair in cases of delayed union, nonunion fractures and spinal fusion procedures. Orthofix also offers a range of external fixation and bracing solutions for orthopedic trauma and deformity correction, catering to both acute injury management and long-term rehabilitative care.

With a presence in over 70 countries, Orthofix serves hospitals, surgery centers and orthopedic practices across North America, Europe, Latin America and the Asia-Pacific region. The company operates manufacturing facilities in the United States and Europe, complemented by a direct sales force and distribution partnerships that extend its reach into emerging markets. Orthofix’s commitment to clinical research and regulatory compliance underpins its global expansion strategy and supports ongoing product innovation.

Founded in 1980 and headquartered in Lewisville, Texas, Orthofix has built a track record of strategic growth through targeted product development and select acquisitions. Under the leadership of President and Chief Executive Officer Brad Mason, the company continues to invest in R&D, new technology platforms and collaborative programs with healthcare providers. Orthofix remains focused on enhancing patient outcomes and delivering value to stakeholders through its specialized orthopedics and spine solutions.

View Orthofix Medical Profile

More Earnings Resources from MarketBeat